*nlm.life
			PubMed Journals: Curr Opin Virol

  Source:		PMID: 31125806


    		Curr Opin Virol. 2019 Apr;35:57-62. doi:
     		10.1016/j.coviro.2019.04.002. Epub 2019 May
			21.

			Nucleoside analogues for the treatment of
			coronavirus infections.

			Pruijssers AJ(1), Denison MR(2).

			Author Information
			(1) Department of Pediatrics, Vanderbilt University
			School of Medicine, Nashville, TN, United
			States; Elizabeth B. Lamb Center for Pediatric
			Research, Vanderbilt University School of
			Medicine, Nashville, TN, United States.
			(2) Department of Pediatrics, Vanderbilt
			University School of Medicine, Nashville,
			TN, United States; Elizabeth B. Lamb Center
			for Pediatric Research, Vanderbilt University
			School of Medicine, Nashville, TN, United
			States; Department of Pathology, Microbiology,
			and Immunology, Vanderbilt University School
			of Medicine, Nashville, TN, United States.
			Electronic address: mark.denison@vumc.org.

			Recent outbreaks of SARS-Coronavirus and MERS-Coronavirus
			(CoV) have heightened awareness about the
			lack of vaccines or antiviral compounds
			approved for prevention or treatment of
			human or potential zoonotic CoVs. Anti-CoV drug
			development has long been challenged by
			the activity of a 3' to 5' proofreading
			exoribonuclease unique to CoVs. Recently,
			a promising nucleoside analogue with broad-spectrum
			activity against CoVs has been identified.
			This review will discuss progress made in
			the development of antiviral nucleoside
			and nucleotide analogues targeting viral RNA synthesis
			as effective therapeutics against CoV infections
			and propose promising strategies for combination
			therapy.

			Copyright © 2019. Published by Elsevier
			B.V.

			DOI: 10.1016/j.coviro.2019.04.002 PMID: 31125806

     			                         Tweet       Print